Bristol-Myers Squibb Company
NYSE: BMY
$54.20
+$0.44 (+0.8%)
Closing Price on October 3, 2024
BMY Articles
These are this morning’s top day trader alerts and most active in price and volume. We have more detailed analysis and data on price and volume with links through to each at VSInvestor.com: JA...
Published:
Diabetes is becoming an epidemic in the U.S. and the Western World. The ties to obesity are often direct, so the potential treatments are often directly tied as well. We did a recent dig down for...
Published:
Last Updated:
Bristol Myers Inc. (NYSE: BMY) plans to spend $2.4 billion to buy partner Medarex Inc. (Nasdaq: MEDX). It will get a great deal beyond the cancer monoclonal antibody that developed together. The...
Published:
Last Updated:
Reuters: Obama says healthcare reform is essential to the recovery. Reuters: CIT (CIT) bond advisers will push for Chapter 11. Reuters: Democrats will fight with banks on consumer agency....
Published:
Last Updated:
Safety and efficacy data are critical to drug candidates. But what really makes a potential drug attractive is strong top-line data, a new biotech-based treatment, and a massive potential market....
Published:
Last Updated:
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
Published:
Reuters: China must balance growth and reducing greenhouse gases. Reuters: The Supreme Court has delayed Chrysler’s Chapter 11. Reuters: The US will allow 10 banks to repay TARP funds....
Published:
Last Updated:
Reuters: GM (GM) will file for Chapter 11 today. Reuters: Geithner told China its dollar assets are safe. Reuters: A judge approved the sale of most of Chrysler’s assets to a group led...
Published:
Last Updated:
We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down...
Published:
These are the top pre-market analyst downgrades and negative research calls we have seen from Wall Street early this Friday morning: Akamai Tech (AKAM) Cut to Hold at Citigroup. Bristol-Myers Squibb...
Published:
It has been no secret that the market for initial public offerings has been one of the biggest ghost towns in the financial markets. The secondary markets and the bond markets are opening up...
Published:
Last Updated:
If you can believe it, there is an initial public offering on deck this week. Bristol-Myers Squibb Co. (NYSE: BMY) is set to partially spin off Mead Johnson Nutrition (NYSE: MJN). It looks like it is...
Published:
Last Updated:
We haven’t been covering Jim Cramer as much for many different reasons, but we still pay attention when he comes out with stock picks because it can still affect at least the short term trading in...
Published:
Last Updated:
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to...
Published:
Last Updated:
People who get to the end of 2008 and are still at work can be thankful. The unemployment rate will probably be over 7%. That does not count the people no longer looking for work. Add them in and the...
Published:
Last Updated: